D-amino-acid oxidase inhibition increases D-serine plasma levels in mouse but not in monkey or dog

Neuropsychopharmacology

Volumn 41, Issue 6, 2016, Pages 1610-1619

  Rojas, Camilo ^a,b   Alt, Jesse ^a   Ator, Nancy A ^b   Thomas, Ajit G ^a   Wu, Ying ^a   Hin, Niyada ^a   Wozniak, Krystyna ^a   Ferraris, Dana ^a   Rais, Rana ^a,b   Tsukamoto, Takashi ^a,b   Slusher, Barbara S ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Department of Molecular and Comparative Pathobiology ^*  (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRO AMINO ACID OXIDASE; DEXTRO AMINO ACID OXIDASE INHIBITOR; ENZYME INHIBITOR; SERINE; UNCLASSIFIED DRUG; 5-CHLOROBENZO(D)ISOXAZOL-3-OL; ISOXAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BABOON; BEAGLE; BINDING AFFINITY; BLOOD LEVEL; CONTROLLED STUDY; DOG; DRUG ABSORPTION; ENZYME INHIBITION; FOLLOW UP; HAPLORHINI; IC50; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEADY STATE; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; METABOLISM; PAPIO HAMADRYAS; SPECIES DIFFERENCE;

ANIMALS; D-AMINO-ACID OXIDASE; DOGS; ISOXAZOLES; MALE; MICE; PAPIO HAMADRYAS; SERINE; SPECIES SPECIFICITY;

EID: 84963499869     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2015.319     Document Type: Article

References (53)

1. Acharya MR, Sparreboom A, Sausville EA, Conley BA, Doroshow JH, Venitz J, et al. (2006). Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor. Cancer Chemother Pharmacol. 57: 275-281.
2. Adage T, Trillat AC, Quattropani A, Perrin D, Cavarec L, Shaw J, et al. (2008). In vitro, and in vivo pharmacological profile of AS057278, a selective d-Amino acid oxidase inhibitor with potential anti-psychotic properties. Eur Neuropsychopharmacol. 18: 200-214.
3. Ator NA. (2000). Zaleplon, and triazolam: drug discrimination, plasma levels, and self-Administration in baboons. Drug Alcohol Depend. 61: 55-68.
4. Bailer AJ. (1988). Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm. 16: 303-309.
5. Berna MJ, Ackermann BL. (2007). Quantification of serine enantiomers in rat brain microdialysate using Marfey's reagent, and LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 846: 359-363.
6. Carone FA, Nakamura S, Goldman B. (1985). Urinary loss of glucose, phosphate, and protein by diffusion into proximal straight tubules injured by D-serine, and maleic acid. Lab Invest. 52: 605-610.
7. Cheng Y, Prusoff WH. (1973). Relationship between the inhibition constant (K1), and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 22: 3099-3108.
8. Chung SP, Sogabe K, Park HK, Song Y, Ono K, Abou El-Magd RM, et al. (2010). Potential cytotoxic effect of hydroxypyruvate produced from D-serine by astroglial D-Amino acid oxidase. J Biochem. 148: 743-753.
9. Cook SP, Galve-Roperh I, Martinez del Pozo A, Rodriguez-Crespo I. (2002). Direct calcium binding results in activation of brain serine racemase. J Biol Chem. 277: 27782-27792.
10. Coyle JT. (2006). Glutamate, and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol. 26: 365-384.
11. Dixon M, Kleppe K. (1965). D-Amino acid oxidase II. Specificity, competitive inhibition, and reaction sequence. Biochimica et Biophysica Acta. 96: 368-382.
12. Duplantier AJ, Becker SL, Bohanon MJ, Borzilleri KA, Chrunyk BA, Downs JT, et al. (2009). Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-Amino acid oxidase (DAAO) inhibitors. J Med Chem. 52: 3576-3585.
13. Ferraris D, Duvall B, Ko YS, Thomas AG, Rojas C, Majer P, et al. (2008). Synthesis, and biological evaluation of D-Amino acid oxidase inhibitors. J Med Chem. 51: 3357-3359.
14. Ferraris DV, Tsukamoto T. (2011). Recent advances in the discovery of D-Amino acid oxidase inhibitors, and their therapeutic utility in schizophrenia. Curr Pharm Des. 17: 103-111.
15. Ganote CE, Peterson DR, Carone FA. (1974). The nature of D-serine-induced nephrotoxicity. Am J Pathol. 77: 269-282.
16. Hashimoto K, Fujita Y, Horio M, Kunitachi S, Iyo M, Ferraris D, et al. (2009). Co-Administration of a D-Amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine. Biol Psychiatry. 65: 1103-1106.
17. Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, et al. (2005). D-serine efficacy as add-on pharmacotherapy to risperidone, and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry. 57: 577-585.
18. Hin N, Duvall B, Ferraris D, Alt J, Thomas AG, Rais R, et al. (2015). 6-Hydroxy-1, 2, 4-Triazine-3, 5(2H, 4H)-dione derivatives as novel d-Amino acid oxidase Inhibitors. J Med Chem. 58: 7258-7272.
19. Huang Y, Nishikawa T, Satoh K, Iwata T, Fukushima T, Santa T, et al. (1998). Urinary excretion of D-serine in human: comparison of different ages, and species. Biol Pharm Bull. 21: 156-162.
20. Iwasa S, Tabara H, Song Z, Nakabayashi M, Yokoyama Y, Fukushima T. (2011). Inhibition of D-Amino acid oxidase activity by antipsychotic drugs evaluated by a fluorometric assay using D-kynurenine as substrate. Yakugaku Zasshi. 131: 1111-1116.
21. Javitt DC, Silipo G, Cienfuegos A, Shelley AM, Bark N, Park M, et al. (2001). Adjunctive high-dose glycine in the treatment of schizophrenia. Int J Neuropsychopharmacol. 4: 385-391.
22. Kaltenbach JP, Ganote CE, Carone FA. (1979). Renal tubular necrosis induced by compounds structurally related to D-serine. Exp Mol Pathol. 30: 209-214.
23. Kantrowitz JT, Malhotra AK, Cornblatt B, Silipo G, Balla A, Suckow RF, et al. (2010). High dose D-serine in the treatment of schizophrenia. Schizophr Res. 121: 125-130.
24. Kawazoe T, Park HK, Iwana S, Tsuge H, Fukui K. (2007). Human D-Amino acid oxidase: an update, and review. Chem Rec 7: 305-315.
25. Kawazoe T, Tsuge H, Imagawa T, Aki K, Kuramitsu S, Fukui K. (2007). Structural basis of D-DOPA oxidation by D-Amino acid oxidase: alternative pathway for dopamine biosynthesis. Biochem Biophys Res Commun. 355: 385-391.
26. Kubota K, Ishizaki T. (1991). Dose-dependent pharmacokinetics of benzoic acid following oral administration of sodium benzoate to humans. Eur J Clin Pharmacol. 41: 363-368.
27. Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE. (2005). Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry. 62: 1196-1204.
28. Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW, et al. (2013). Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-Amino acid oxidase inhibitor. JAMA Psychiatry. 70: 1267-1275.
29. Lane HY, Lin CH, Huang YJ, Liao CH, Chang YC, Tsai GE. (2010) A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine), and D-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol. 13: 451-460.
30. Lukas SE, Griffiths RR, Bradford LD, Brady JV, Daley L. (1982) A tethering system for intravenous, and intragastric drug administration in the baboon. Pharmacol Biochem Behav. 17: 823-829.
31. Maekawa M, Okamura T, Kasai N, Hori Y, Summer KH, Konno R. (2005). D-Amino-Acid oxidase is involved in D-serine-induced nephrotoxicity. Chem Res Toxicol. 18: 1678-1682.
32. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, et al. (1997). Ketamine-induced exacerbation of psychotic symptoms, and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology. 17: 141-150.
33. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, et al. (1996). NMDA receptor function, and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology. 14: 301-307.
34. Miyoshi Y, Hamase K, Tojo Y, Mita M, Konno R, Zaitsu K. (2009). Determination of D-serine, and D-Alanine in the tissues, and physiological fluids of mice with various D-Amino-Acid oxidase activities using two-dimensional high-performance liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci. 877: 2506-2512.
35. Molla G, Sacchi S, Bernasconi M, Pilone MS, Fukui K, Polegioni L. (2006). Characterization of human D-Amino acid oxidase. FEBS Lett. 580: 2358-2364.
36. Morehead RP, Poe WD, et al. (1946). The influence of age, and species on the nephrotoxic action of d1-serine. Am J Pathol. 22: 658.
37. Mothet JP, Parent AT, Wolosker H, Brady RO Jr, Linden DJ, Ferris CD, et al. (2000). D-serine is an endogenous ligand for the glycine site of the N-methyl-D-Aspartate receptor. Proc Natl Acad Sci USA. 97: 4926-4931.
38. Nutt JG, Woodward WR, Anderson JL. (1985). The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism. Ann Neurol. 18: 537-543.
39. Ogaya T, Song Z, Ishii K, Fukushima T. (2010). Changes in extracellular kynurenic acid concentrations in rat prefrontal cortex after D-kynurenine infusion: an in vivo microdialysis study. Neurochem Res. 35: 559-563.
40. Oldendorf WH. (1971). Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. Am J Physiol. 221: 1629-1639.
41. Pollegioni L, Piubelli L, Sacchi S, Pilone MS, Molla G. (2007). Physiological functions of D-Amino acid oxidases: from yeast to humans. Cell Mol Life Sci. 64: 1373-1394.
42. Rais R, Thomas AG, Wozniak K, Wu Y, Jaaro-Peled H, Sawa A, et al. (2012). Pharmacokinetics of oral D-serine in D-Amino acid oxidase knockout mice. Drug Metab Dispos. 40: 2067-2073.
43. Sacchi S, Bernasconi M, Martineau M, Mothet JP, Ruzzene M, Pilone MS, et al. (2008). pLG72 modulates intracellular D-serine levels through its interaction with D-Amino acid oxidase: effect on schizophrenia susceptibility. J Biol Chem. 283: 22244-22256.
44. Smith SM, Uslaner JM, Hutson PH. (2010). The therapeutic potential of D-Amino acid oxidase (DAAO) inhibitors. Open Med Chem J 4: 3-9.
45. Smith SM, Uslaner JM, Yao L, Mullins CM, Surles NO, Huszar SL, et al. (2009). The behavioral, and neurochemical effects of a novel D-Amino acid oxidase inhibitor compound 8 [4H-Thieno [3, 2-b] pyrrole-5-carboxylic acid], and D-serine. J Pharmacol Exp Ther. 328: 921-930.
46. Tishkov VI, Khoronenkova SV. (2005). D-Amino acid oxidase: structure, catalytic mechanism, and practical application. Biochemistry (Mosc) 70: 40-54.
47. Tsai G, Yang P, Chung LC, Lange N, Coyle JT. (1998). D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 44: 1081-1089.
48. Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT. (1999). D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry. 156: 1822-1825.
49. Vanoni MA, Cosma A, Mazzeo D, Mattevi A, Todone F, Curti B. (1997). Limited proteolysis, and X-ray crystallography reveal the origin of substrate specificity, and of the rate-limiting product release during oxidation of D-Amino acids catalyzed by mammalian D-Amino acid oxidase. Biochemistry. 36: 5624-5632.
50. Verrall L, Walker M, Rawlings N, Benzel I, Kew JN, Harrison PJ, et al. (2007). d-Amino acid oxidase, and serine racemase in human brain: normal distribution, and altered expression in schizophrenia. Eur J Neurosci. 26: 1657-1669.
51. Weiser M, Heresco-Levy U, Davidson M, Javitt DC, Werbeloff N, Gershon AA, et al. (2012) A multicenter, add-on randomized controlled trial of low-dose d-serine for negative, and cognitive symptoms of schizophrenia. J Clin Psychiatry. 73: e728-e734.
52. Williams RE, Lock EA. (2005). Sodium benzoate attenuates D-serine induced nephrotoxicity in the rat. Toxicology. 207: 35-48.
53. Yang CR, Svensson KA. (2008). Allosteric modulation of NMDA receptor via elevation of brain glycine, and D-serine: the therapeutic potentials for schizophrenia. Pharmacol Ther. 120: 317-332.